Literature DB >> 8618883

Differential recognition of the type I interferon receptor by interferons tau and alpha is responsible for their disparate cytotoxicities.

P S Subramaniam1, S A Khan, C H Pontzer, H M Johnson.   

Abstract

Interferon tau (IFN tau), originally identified as a pregnancy recognition hormone, is a type I interferon that is related to the various IFN alpha species (IFN alpha s). Ovine IFN tau has antiviral activity similar to that of human IFN alpha A on the Madin-Darby bovine kidney (MDBK) cell line and is equally effective in inhibiting cell proliferation. In this study, IFN tau was found to differ from IFN alpha A in that is was > 30-fold less toxic to MDBK cells at high concentrations. Excess IFN tau did not block the cytotoxicity of IFN alpha A on MDBK cells, suggesting that these two type I IFNs recognize the type I IFN receptor differently on these cells. In direct binding studies, 125I-IFN tau had a Kd of 3.90 x 10(-10) M for receptor on MDBK cells, whereas that of 125I-IFN alpha A was 4.45 x 10(-11) M. Consistent with the higher binding affinity, IFN alpha A was severalfold more effective than IFN tau in competitive binding against 125I-IFN tau to receptor on MDBK cells. Paradoxically, the two IFNs had similar specific antiviral activities on MDBK cells. However, maximal IFN antiviral activity required only fractional occupancy of receptors, whereas toxicity was associated with maximal receptor occupancy. Hence, IFN alpha A, with the higher binding affinity, was more toxic than IFN tau. The IFNs were similar in inducing the specific phosphorylation of the type I receptor-associated tyrosine kinase Tyk2, and the transcription factors Stat1 alpha and Stat2, suggesting that phosphorylation of these signal transduction proteins is not involved in the cellular toxicity associated with type I IFNs. Experiments using synthetic peptides suggest that differences in the interaction at the N terminal of IFN tau and IFN alpha with the type I receptor complex contribute significantly to differences in high-affinity equilibrium binding of these molecules. It is postulated that such a differential recognition of the receptor is responsible for the similar antiviral but different cytotoxic effects of these IFNs. Moreover, these data imply that receptors are "spare'' with respect to certain biological properties, and we speculate that IFNs may induce a concentration-dependent selective association of receptor subunits.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8618883      PMCID: PMC40338          DOI: 10.1073/pnas.92.26.12270

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  19 in total

1.  Stimulation of 2',5'-oligoadenylate synthetase activity in sheep endometrium during pregnancy, by intrauterine infusion of ovine trophoblast protein-1, and by intramuscular administration of recombinant bovine interferon-alpha I1.

Authors:  M A Mirando; E C Short; R D Geisert; J L Vallet; F W Bazer
Journal:  J Reprod Fertil       Date:  1991-11

2.  Antiproliferative activity of a pregnancy recognition hormone, ovine trophoblast protein-1.

Authors:  C H Pontzer; F W Bazer; H M Johnson
Journal:  Cancer Res       Date:  1991-10-01       Impact factor: 12.701

Review 3.  The interferon receptors.

Authors:  M Rubinstein; P Orchansky
Journal:  CRC Crit Rev Biochem       Date:  1986

4.  Procedures for studying binding of interferon to human cells in suspension cultures.

Authors:  J A Langer; S Pestka
Journal:  Methods Enzymol       Date:  1986       Impact factor: 1.600

5.  Localization of an antiviral site on the pregnancy recognition hormone, ovine trophoblast protein 1.

Authors:  C H Pontzer; T L Ott; F W Bazer; H M Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

6.  Antiviral activity of the pregnancy recognition hormone ovine trophoblast protein-1.

Authors:  C H Pontzer; B A Torres; J L Vallet; F W Bazer; H M Johnson
Journal:  Biochem Biophys Res Commun       Date:  1988-04-29       Impact factor: 3.575

7.  Procedures for studying the binding of interferon to human and bovine cells in monolayer culture.

Authors:  K C Zoon; D Zur Nedden; H Arnheiter
Journal:  Methods Enzymol       Date:  1986       Impact factor: 1.600

8.  Analysis of radioligand binding experiments. A collection of computer programs for the IBM PC.

Authors:  G A McPherson
Journal:  J Pharmacol Methods       Date:  1985-11

9.  Cytopathic effect inhibition assay for interferon: microculture plate assay.

Authors:  J A Armstrong
Journal:  Methods Enzymol       Date:  1981       Impact factor: 1.600

10.  The IFN pregnancy recognition hormone IFN-tau blocks both development and superantigen reactivation of experimental allergic encephalomyelitis without associated toxicity.

Authors:  J M Soos; P S Subramaniam; A C Hobeika; J Schiffenbauer; H M Johnson
Journal:  J Immunol       Date:  1995-09-01       Impact factor: 5.422

View more
  21 in total

1.  Effects of type I/type II interferons and transforming growth factor-beta on B-cell differentiation and proliferation. Definition of costimulation and cytokine requirements for immunoglobulin synthesis and expression.

Authors:  D M Estes; W Tuo; W C Brown; J Goin
Journal:  Immunology       Date:  1998-12       Impact factor: 7.397

2.  Type I interferon mimetics bypass vaccinia virus decoy receptor virulence factor for protection of mice against lethal infection.

Authors:  Chulbul M Ahmed; Howard M Johnson
Journal:  Clin Vaccine Immunol       Date:  2014-06-25

3.  Kinetics of cytokine receptor trafficking determine signaling and functional selectivity.

Authors:  Jonathan Martinez-Fabregas; Stephan Wilmes; Luopin Wang; Majid Kazemian; Suman Mitra; Ignacio Moraga; Maximillian Hafer; Elizabeth Pohler; Juliane Lokau; Christoph Garbers; Adeline Cozzani; Paul K Fyfe; Jacob Piehler
Journal:  Elife       Date:  2019-11-27       Impact factor: 8.140

Review 4.  Functions of interferon tau as an immunological regulator for establishment of pregnancy.

Authors:  Hanako Bai; Toshihiro Sakurai; Hiroshi Fujiwara; Atsushi Ideta; Yoshito Aoyagi; James D Godkin; Kazuhiko Imakawa
Journal:  Reprod Med Biol       Date:  2012-01-25

5.  Short peptide type I interferon mimetics: therapeutics for experimental allergic encephalomyelitis, melanoma, and viral infections.

Authors:  Chulbul M Ahmed; Howard M Johnson
Journal:  J Interferon Cytokine Res       Date:  2014-05-08       Impact factor: 2.607

6.  Molecular interactions between Bos taurus interferon-tau1c and human type I interferon receptor.

Authors:  Vishawdeep Singh Jamwal; Gourav Modi; Aman George; Manmohan Singh Chauhan
Journal:  Bioinformation       Date:  2009-10-13

7.  A Recombinant Adenovirus Expressing Ovine Interferon Tau Prevents Influenza Virus-Induced Lethality in Mice.

Authors:  V Martín; E Pascual; M Avia; G Rangel; A de Molina; A Alejo; N Sevilla
Journal:  J Virol       Date:  2016-01-06       Impact factor: 5.103

8.  Type I IFN receptor controls activated TYK2 in the nucleus: implications for EAE therapy.

Authors:  Chulbul M Ahmed; Ezra N Noon-Song; Kaisa Kemppainen; Massimo P Pascalli; Howard M Johnson
Journal:  J Neuroimmunol       Date:  2012-10-27       Impact factor: 3.478

9.  Anti-human immunodeficiency virus activity of tau interferon in human macrophages: involvement of cellular factors and beta-chemokines.

Authors:  Christine Rogez; Marc Martin; Nathalie Dereuddre-Bosquet; Jacques Martal; Dominique Dormont; Pascal Clayette
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

10.  Instructive roles for cytokine-receptor binding parameters in determining signaling and functional potency.

Authors:  Ignacio Moraga; David Richter; Stephan Wilmes; Hauke Winkelmann; Kevin Jude; Christoph Thomas; Megan M Suhoski; Edgar G Engleman; Jacob Piehler; K Christopher Garcia
Journal:  Sci Signal       Date:  2015-11-10       Impact factor: 8.192

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.